Factors influencing patients' acceptance and adherence to active surveillance
- PMID: 23271775
- PMCID: PMC3540870
- DOI: 10.1093/jncimonographs/lgs024
Factors influencing patients' acceptance and adherence to active surveillance
Abstract
Clinical decision making in localized prostate cancer is a complicated, multidimensional process in which men often consider their own personal preferences, the advice of their healthcare providers, the opinions of their family and friends, and outside information sources. They synthesize all of this within the framework of their own unique socioeconomic situation, their social support network, and their preconceived impressions of their health and the health-care system. This is particularly germane when considering factors that influence a patient's acceptance of and adherence to active surveillance (AS). We propose a conceptual framework based on a previously described systematic-heuristic theoretical model of decision making in this setting. We identify a number of factors that patients systematically prioritize when considering AS. These include desire for cancer control or cure, age at diagnosis, and concern regarding side effects of treatment. The way patients value these factors and effectively decide on treatment is influenced by more heuristic factors, including physician recommendation, opinion of friends and family members, and overall decision uncertainty. These heuristic factors also play an important role in adherence when a patient elects AS. Finally, some of the factors, particularly the heuristic ones, are potentially modifiable and may serve as targets for future interventions to increase acceptance of and adherence to AS.
Figures
Similar articles
-
Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer.BJU Int. 2011 Dec;108(11):1787-93. doi: 10.1111/j.1464-410X.2011.10200.x. Epub 2011 Apr 20. BJU Int. 2011. PMID: 21507187
-
Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance.Patient Educ Couns. 2012 Jun;87(3):369-74. doi: 10.1016/j.pec.2011.11.009. Epub 2011 Dec 15. Patient Educ Couns. 2012. PMID: 22177658
-
Improving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions.J Natl Cancer Inst Monogr. 2012 Dec;2012(45):197-201. doi: 10.1093/jncimonographs/lgs023. J Natl Cancer Inst Monogr. 2012. PMID: 23271773 Free PMC article.
-
An evidence review of active surveillance in men with localized prostate cancer.Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Evid Rep Technol Assess (Full Rep). 2011. PMID: 23126653 Free PMC article. Review.
-
Patient and disease factors affecting the choice and adherence to active surveillance.Curr Opin Urol. 2015 May;25(3):272-6. doi: 10.1097/MOU.0000000000000154. Curr Opin Urol. 2015. PMID: 25692724 Review.
Cited by
-
Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study.Cancer Med. 2024 Jan;13(1):e6847. doi: 10.1002/cam4.6847. Epub 2023 Dec 27. Cancer Med. 2024. PMID: 38151901 Free PMC article.
-
Active surveillance for thyroid Cancer: a qualitative study of barriers and facilitators to implementation.BMC Cancer. 2021 Apr 28;21(1):471. doi: 10.1186/s12885-021-08230-8. BMC Cancer. 2021. PMID: 33910527 Free PMC article.
-
Patients' Reaction to Diagnosis with Thyroid Cancer or an Indeterminate Thyroid Nodule.Thyroid. 2021 Apr;31(4):580-588. doi: 10.1089/thy.2020.0233. Epub 2020 Nov 4. Thyroid. 2021. PMID: 33012267 Free PMC article.
-
Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature.Curr Oncol Rep. 2020 Jul 28;22(10):101. doi: 10.1007/s11912-020-00962-3. Curr Oncol Rep. 2020. PMID: 32725550 Free PMC article.
-
Recommendations from primary care physicians, family, friends and work colleagues influence patients' decisions related to hepatitis screening, medical examinations and antiviral treatment.Exp Ther Med. 2020 Apr;19(4):2973-2982. doi: 10.3892/etm.2020.8533. Epub 2020 Feb 18. Exp Ther Med. 2020. PMID: 32256783 Free PMC article.
References
-
- Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 2010; 8(2):145 - PubMed
-
- Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177(6):2106–2131 - PubMed
-
- Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001; 93(24):1864–1871 - PubMed
-
- Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer. 2006; 106(9):1865–1874 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
